Skip to content

The Effect of Transcutaneous Electrical Acupoint Stimulation on Postoperative Nausea and Vomiting in Diabetic Patients Undergoing Laparoscopic Surgery: A Randomized Controlled Trial

The Effect of Transcutaneous Electrical Acupoint Stimulation on Postoperative Nausea and Vomiting in Diabetic Patients Undergoing Laparoscopic Surgery: A Randomized Controlled Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500104453
Enrollment
Unknown
Registered
2025-06-17
Start date
2025-04-16
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postoperative nausea and vomiting

Interventions

Experimental Group (Group T):Group T: Thirty minutes before anesthesia induction, TEAS (Transcutaneous Electrical Acupoint Stimulation) was applied to the bilateral Neiguan (PC6), Hegu (LI4), and Zusa
Control Group (Group P):Routine anesthesia was performed, with electrode patches applied only at the same time points and acupoints, without stimulation.

Sponsors

The First Affiliated Hospital of Xi'an Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients scheduled to undergo elective laparoscopic surgery under general anesthesia and diagnosed with diabetes; 2. Aged 18 to 65 years, regardless of gender; 3. ASA (American Society of Anesthesiologists) classification of I to III; 4. Anesthesia duration of 1 to 3 hours; 5. Apfel score >= 2; 6. Requiring postoperative analgesic pump and having signed an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients who experienced vomiting and/or retching, nausea within 24 hours before surgery (excluding vomiting and/or retching, nausea caused by gastrointestinal preparation); 2. Patients with a history of vestibular disorders (including but not limited to: peripheral vestibular syndrome, central vestibular syndrome, etc.) or dizziness, or a history of gastrointestinal, central nervous system, or other systemic diseases that may cause nausea and vomiting; 3. Patients with local skin infection or damage at the acupoint sites; 4. Patients who require conversion to open abdominal surgery during the procedure; 5. Patients with known allergies or contraindications to 5-HT3 receptor antagonists or other drugs that may be used during the trial; 6. Patients who require transfer to the intensive care unit (ICU) for treatment after surgery.

Design outcomes

Primary

MeasureTime frame
The incidence and severity of postoperative nausea and vomiting;

Secondary

MeasureTime frame
mean arterial pressure, MAP;Heart Rate;Time of rescue medication administration;PONV-associated adverse effects;

Countries

China

Contacts

Public ContactZhao Ling

The First Affiliated Hospital of Xi'an Medical University

sisi79820@163.com+86 177 9185 9818

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026